Skip to main content
Top
Gepubliceerd in: Quality of Life Research 5/2013

01-06-2013

Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinson’s disease

Auteurs: Megan K. Young, Shu-Kay Ng, George Mellick, Paul A. Scuffham

Gepubliceerd in: Quality of Life Research | Uitgave 5/2013

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

The EuroQoL (EQ-5D) is ideal to compare quality of life across conditions. However, the Parkinson’s Disease Questionnaire (PDQ-39) is often the only quality-of-life instrument used in Parkinson’s disease research. We aimed to identify associations between PDQ-39 domains and EQ-5D domains, and compare different methods of developing a function to map the PDQ-39 to EQ-5D scores.

Methods

Adults with Parkinson’s disease self-completed both instruments. Ordinal regression identified associations between PDQ-39 domain scores and each EQ-5D domain. Modeling (n = 80) and validation sets (n = 16) were randomly generated. Overall performance of four methods of mapping the PDQ-39 to EQ-5D scores (using PDQ-39 domains and total score in ordinal and linear regression) was assessed with the validation set, followed by assessing the equivalence of observed and predicted EQ-5D scores on the full dataset controlling for sociodemographic factors.

Results

Different sets of PDQ-39 domains were associated with each EQ-5D domain. For example, PDQ-39 “Activities of Daily Living” and “Social Support” were associated with EQ-5D “Personal Care,” while PDQ-39 “Emotional Well-being” was associated with EQ-5D “Anxiety/Depression.” Over one-third (37.5 %) of predictions from ordinal regressions had an error <0.01 % (compared to 6.3 % for linear regressions). The EQ-5D scores predicted with ordinal regression using PDQ-39 domains were similar in distribution and association with sociodemographic factors to the observed EQ-5D scores.

Conclusions

Of the four methods tested, using PDQ-39 domains in ordinal regression was superior for mapping EQ-5D scores. The function reported here may prove particularly useful for cost-utility analyses comparing Parkinson’s disease with other conditions.
Literatuur
1.
go back to reference Winter, Y., von Campenhausen, S., Gasser, J., Seppi, K., Reese, J. P., et al. (2010). Social and clinical determinants of quality of life in Parkinson’s disease in Austria: A cohort study. Journal of Neurology, 257, 638–645.PubMedCrossRef Winter, Y., von Campenhausen, S., Gasser, J., Seppi, K., Reese, J. P., et al. (2010). Social and clinical determinants of quality of life in Parkinson’s disease in Austria: A cohort study. Journal of Neurology, 257, 638–645.PubMedCrossRef
2.
go back to reference Rahman, S., Griffin, H. J., Quinn, N. P., & Jahanshahi, M. (2008). Quality of life in Parkinson’s disease: The relative importance of the symptoms. Movement Disorders, 23(10), 1428–1434.PubMedCrossRef Rahman, S., Griffin, H. J., Quinn, N. P., & Jahanshahi, M. (2008). Quality of life in Parkinson’s disease: The relative importance of the symptoms. Movement Disorders, 23(10), 1428–1434.PubMedCrossRef
3.
go back to reference Peto, V., Jenkinson, C., & Fitzpatrick, R. (1998). PDQ-39: A review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. Journal of Neurology, 245(suppl 1), s10–s14.PubMedCrossRef Peto, V., Jenkinson, C., & Fitzpatrick, R. (1998). PDQ-39: A review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. Journal of Neurology, 245(suppl 1), s10–s14.PubMedCrossRef
4.
go back to reference Tickle-Degnen, L., Ellis, T., Saint-Hilaire, M. H., Thomas, C. A., & Wagenaar, R. C. (2010). Self-management rehabilitation and health-related quality of life in Parkinson’s disease: A randomized controlled trial. Movement Disorders, 25(2), 194–204.PubMedCrossRef Tickle-Degnen, L., Ellis, T., Saint-Hilaire, M. H., Thomas, C. A., & Wagenaar, R. C. (2010). Self-management rehabilitation and health-related quality of life in Parkinson’s disease: A randomized controlled trial. Movement Disorders, 25(2), 194–204.PubMedCrossRef
5.
go back to reference Klepac, N., Hajnsek, S., & Trkulja, V. (2010). Impact of pre-morbid depression on health-related quality of life in non-demented Parkinson’s disease patients. Parkinsonism and Related Disorders, 16, 21–27.PubMedCrossRef Klepac, N., Hajnsek, S., & Trkulja, V. (2010). Impact of pre-morbid depression on health-related quality of life in non-demented Parkinson’s disease patients. Parkinsonism and Related Disorders, 16, 21–27.PubMedCrossRef
6.
go back to reference Scalzo, P., Kummer, A., Cardoso, F., & Teixeira, A. L. (2009). Depressive symptoms and perception of quality of life in Parkinson’s disease. Arquivos De Neuro-Psiquiatria, 67(2-A), 203–208. Scalzo, P., Kummer, A., Cardoso, F., & Teixeira, A. L. (2009). Depressive symptoms and perception of quality of life in Parkinson’s disease. Arquivos De Neuro-Psiquiatria, 67(2-A), 203–208.
7.
go back to reference Schrag, A., Geser, F., Stampfer-Kountchev, M., Seppi, K., Sawires, M., et al. (2006). Health-related quality of life in multiple system atrophy. Movement Disorders, 21(6), 809–815.PubMedCrossRef Schrag, A., Geser, F., Stampfer-Kountchev, M., Seppi, K., Sawires, M., et al. (2006). Health-related quality of life in multiple system atrophy. Movement Disorders, 21(6), 809–815.PubMedCrossRef
8.
go back to reference Schrag, A., Selai, C., Jahanshahi, M., & Quinn, N. P. (2000). The EQ-5D—a generic quality of life measure – is a useful instrument to measure quality of life in patients with Parkinson’s disease. Journal of Neurology Neurosurgery and Psychiatry, 69, 67–73.CrossRef Schrag, A., Selai, C., Jahanshahi, M., & Quinn, N. P. (2000). The EQ-5D—a generic quality of life measure – is a useful instrument to measure quality of life in patients with Parkinson’s disease. Journal of Neurology Neurosurgery and Psychiatry, 69, 67–73.CrossRef
9.
go back to reference Kristiansen, I. S., Bingefors, K., Nyholm, D., & Isacson, D. (2009). Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson’s disease in Sweden: An exploratory study. Applied Health Economics and Health Policy, 7(3), 167–180.PubMedCrossRef Kristiansen, I. S., Bingefors, K., Nyholm, D., & Isacson, D. (2009). Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson’s disease in Sweden: An exploratory study. Applied Health Economics and Health Policy, 7(3), 167–180.PubMedCrossRef
10.
go back to reference Groenendaal, H., Tarrants, M. L., & Armand, C. (2010). Treatment of advanced Parkinson’s disease in the United States. Clinical Drug Intestig, 30(11), 789–798.CrossRef Groenendaal, H., Tarrants, M. L., & Armand, C. (2010). Treatment of advanced Parkinson’s disease in the United States. Clinical Drug Intestig, 30(11), 789–798.CrossRef
11.
go back to reference Haycox, A., Armand, C., Murteira, S., Cochran, J., & Francois, C. (2009). Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson’s disease in the UK setting. Drugs and Aging, 26(9), 791–801.PubMedCrossRef Haycox, A., Armand, C., Murteira, S., Cochran, J., & Francois, C. (2009). Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson’s disease in the UK setting. Drugs and Aging, 26(9), 791–801.PubMedCrossRef
12.
go back to reference Valldeoriola, F., Morsi, O., Tolosa, E., Rumia, J., Marti, M. J., et al. (2007). Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson’s disease. Movement Disorders, 22(15), 2183–2191.PubMedCrossRef Valldeoriola, F., Morsi, O., Tolosa, E., Rumia, J., Marti, M. J., et al. (2007). Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson’s disease. Movement Disorders, 22(15), 2183–2191.PubMedCrossRef
13.
go back to reference Winter, Y., von Campenhausen, S., Popov, G., Reese, J. P., Balzer-Geldsetzer, M., et al. (2010). Social and clnical determinants of quality of life in Parkinson’s disease in a Russian cohort study. Parkinsonism and Related Disorders, 16, 243–248.PubMedCrossRef Winter, Y., von Campenhausen, S., Popov, G., Reese, J. P., Balzer-Geldsetzer, M., et al. (2010). Social and clnical determinants of quality of life in Parkinson’s disease in a Russian cohort study. Parkinsonism and Related Disorders, 16, 243–248.PubMedCrossRef
14.
go back to reference Post, B., Muslimovic, D., van Geloven, N., Speelman, J. D., Schmand, B., et al. (2011). Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson’s disease. Movement Disorders, 26(3), 449–456.PubMedCrossRef Post, B., Muslimovic, D., van Geloven, N., Speelman, J. D., Schmand, B., et al. (2011). Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson’s disease. Movement Disorders, 26(3), 449–456.PubMedCrossRef
15.
go back to reference Visser, M., Verbaan, D., van Rooden, S., Marinus, J., van Hilten, J., et al. (2009). A longitudinal evaluation of health-related quality of life of patients with Parkinson’s disease. Value in Health, 12(2), 392–396.PubMedCrossRef Visser, M., Verbaan, D., van Rooden, S., Marinus, J., van Hilten, J., et al. (2009). A longitudinal evaluation of health-related quality of life of patients with Parkinson’s disease. Value in Health, 12(2), 392–396.PubMedCrossRef
16.
go back to reference Hristova, D. R., Hristov, J. I., Mateva, N. G., & Papathanasiou, J. V. (2009). Quality of life in patients with Parkinson’s disease. Folia Medica, 51(4), 58–64.PubMed Hristova, D. R., Hristov, J. I., Mateva, N. G., & Papathanasiou, J. V. (2009). Quality of life in patients with Parkinson’s disease. Folia Medica, 51(4), 58–64.PubMed
17.
go back to reference Bucks, R. S., Cruise, K. E., Skinner, T. C., Loftus, A. M., Barker, R. A., & Thomas, M. G. (2011). Coping processes and health-related quality of life in Parkinson’s disease. International Journal of Geriatric Psychiatry, 26, 247–255.PubMedCrossRef Bucks, R. S., Cruise, K. E., Skinner, T. C., Loftus, A. M., Barker, R. A., & Thomas, M. G. (2011). Coping processes and health-related quality of life in Parkinson’s disease. International Journal of Geriatric Psychiatry, 26, 247–255.PubMedCrossRef
18.
go back to reference Cheung, Y. B., Tan, L. C. S., Lau, P. N., Au, W. L., & Luo, N. (2008). Mapping the eight-item Parkinson’s Disease Questionnaire (PDQ-8) to the EQ-5D utility index. Quality of Life Research, 17, 1173–1181.PubMedCrossRef Cheung, Y. B., Tan, L. C. S., Lau, P. N., Au, W. L., & Luo, N. (2008). Mapping the eight-item Parkinson’s Disease Questionnaire (PDQ-8) to the EQ-5D utility index. Quality of Life Research, 17, 1173–1181.PubMedCrossRef
19.
go back to reference Jenkinson, C., Fitzpatrick, R., & Peto, V. (2012). The Parkinson’s Disease Questionnaire: User Manual for the PDQ-39, PDQ-8 and the PDQ Summary Index. Oxford: University of Oxford Health Services Research Unit; 1998. © Copyright, Isis Innovation Limited 1993. All Rights Reserved. The authors, being Professor Crispin Jenkinson, Professor Ray Fitzpatrick and Ms Viv Peto, have asserted their moral rights. Jenkinson, C., Fitzpatrick, R., & Peto, V. (2012). The Parkinson’s Disease Questionnaire: User Manual for the PDQ-39, PDQ-8 and the PDQ Summary Index. Oxford: University of Oxford Health Services Research Unit; 1998. © Copyright, Isis Innovation Limited 1993. All Rights Reserved. The authors, being Professor Crispin Jenkinson, Professor Ray Fitzpatrick and Ms Viv Peto, have asserted their moral rights.
20.
go back to reference Cheung, K., Oemar, M., Oppe, M., Rabin, R. (2009). EQ-5D User Guide: Basic information on how to use EQ-5D Version 2.0. EuroQol Group. Cheung, K., Oemar, M., Oppe, M., Rabin, R. (2009). EQ-5D User Guide: Basic information on how to use EQ-5D Version 2.0. EuroQol Group.
21.
22.
go back to reference Jenkinson, C., Heffernan, C., Doll, H., & Fitzpatrick, R. (2006). The Parkinson’s Disease Questionnaire (PDQ-39): Evidence for a method of imputing missing data. Age and Ageing, 35, 497–502.PubMedCrossRef Jenkinson, C., Heffernan, C., Doll, H., & Fitzpatrick, R. (2006). The Parkinson’s Disease Questionnaire (PDQ-39): Evidence for a method of imputing missing data. Age and Ageing, 35, 497–502.PubMedCrossRef
23.
go back to reference Ng, S. K., Krishnan, T., & McLachlan, G. J. (2004). The EM algorithm. In J. Gentle, W. Hardle, & Y. Mori (Eds.), Handbook of computational statistics (Vol. 1, pp. 137–168). New York: Springer. Ng, S. K., Krishnan, T., & McLachlan, G. J. (2004). The EM algorithm. In J. Gentle, W. Hardle, & Y. Mori (Eds.), Handbook of computational statistics (Vol. 1, pp. 137–168). New York: Springer.
24.
go back to reference Little, R. J. A., & Rubin, D. B. (2002). Statistical analysis with missing data (2nd ed.). New York: Wiley. Little, R. J. A., & Rubin, D. B. (2002). Statistical analysis with missing data (2nd ed.). New York: Wiley.
25.
go back to reference Brant, R. (1990). Assessing proportionality in the proportional odds model for ordinal logistic regression. Biometrics, 46, 1171–1178.PubMedCrossRef Brant, R. (1990). Assessing proportionality in the proportional odds model for ordinal logistic regression. Biometrics, 46, 1171–1178.PubMedCrossRef
26.
go back to reference Xie, F., Pullenayegum, E. M., Li, S. C., Hopkins, R., Thumboo, J., & Lo, N. N. (2010). Use of a disease-specific instrument in economic evaluations: Mapping WOMAC onto the EQ-5D utility index. Value in Health, 13, 873–878.PubMedCrossRef Xie, F., Pullenayegum, E. M., Li, S. C., Hopkins, R., Thumboo, J., & Lo, N. N. (2010). Use of a disease-specific instrument in economic evaluations: Mapping WOMAC onto the EQ-5D utility index. Value in Health, 13, 873–878.PubMedCrossRef
27.
go back to reference Sullivan, P. W., & Ghushchyan, V. (2006). Preference-based EQ-5D index scores for chronic conditions in the United States. Medical Decision Making, 26, 410–420.PubMedCrossRef Sullivan, P. W., & Ghushchyan, V. (2006). Preference-based EQ-5D index scores for chronic conditions in the United States. Medical Decision Making, 26, 410–420.PubMedCrossRef
28.
go back to reference Lawrence, W. F., Jr, & Fleishman, J. A. (2004). Predicting EuroQoL EQ-5D preference scores from the SF-12 Health Survey in a nationally representative sample. Medical Decision Making, 24, 160–169.PubMedCrossRef Lawrence, W. F., Jr, & Fleishman, J. A. (2004). Predicting EuroQoL EQ-5D preference scores from the SF-12 Health Survey in a nationally representative sample. Medical Decision Making, 24, 160–169.PubMedCrossRef
29.
go back to reference Sullivan, P. W., & Ghushchyan, V. (2006). Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample. Medical Decision Making, 26, 401–409.PubMedCrossRef Sullivan, P. W., & Ghushchyan, V. (2006). Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample. Medical Decision Making, 26, 401–409.PubMedCrossRef
30.
go back to reference Luo, N., Johnson, J. A., Shaw, J. W., Feeny, D., & Coons, S. J. (2005). Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and health utilities index. Medical Care, 43, 1078–1086.PubMedCrossRef Luo, N., Johnson, J. A., Shaw, J. W., Feeny, D., & Coons, S. J. (2005). Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and health utilities index. Medical Care, 43, 1078–1086.PubMedCrossRef
31.
go back to reference Pullenayegum, E. M., Tarride, J. E., Xie, F., Goeree, R., Gerstein, H. C., & O’Reilly, D. (2010). Analysis of health utility data when some subjects attain the upper bound of 1: Are Tobit and CLAD models appropriate? Value in Health, 13, 487–494.PubMedCrossRef Pullenayegum, E. M., Tarride, J. E., Xie, F., Goeree, R., Gerstein, H. C., & O’Reilly, D. (2010). Analysis of health utility data when some subjects attain the upper bound of 1: Are Tobit and CLAD models appropriate? Value in Health, 13, 487–494.PubMedCrossRef
32.
go back to reference Hagell, P., Whalley, D., McKenna, S. P., & Lindvall, O. (2003). Health status measurement in Parkinson’s disease: Validity of the PDQ-39 and Nottingham health profile. Movement Disorders, 18, 773–783.PubMedCrossRef Hagell, P., Whalley, D., McKenna, S. P., & Lindvall, O. (2003). Health status measurement in Parkinson’s disease: Validity of the PDQ-39 and Nottingham health profile. Movement Disorders, 18, 773–783.PubMedCrossRef
Metagegevens
Titel
Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinson’s disease
Auteurs
Megan K. Young
Shu-Kay Ng
George Mellick
Paul A. Scuffham
Publicatiedatum
01-06-2013
Uitgeverij
Springer Netherlands
Gepubliceerd in
Quality of Life Research / Uitgave 5/2013
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-012-0231-6

Andere artikelen Uitgave 5/2013

Quality of Life Research 5/2013 Naar de uitgave